- Home
- ARTV vs ITOS Comparison
ARTV vs ITOS Comparison
Compare ARTV & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTV
- ITOS
- Stock Information
- Founded
- ARTV 2019
- ITOS 2011
- Country
- ARTV United States
- ITOS United States
- Employees
- ARTV N/A
- ITOS N/A
- Industry
- ARTV
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARTV
- ITOS Health Care
- Exchange
- ARTV NYSE
- ITOS Nasdaq
- Market Cap
- ARTV 275.7M
- ITOS 283.9M
- IPO Year
- ARTV 2024
- ITOS 2020
- Fundamental
- Price
- ARTV $10.86
- ITOS $7.59
- Analyst Decision
- ARTV Strong Buy
- ITOS Strong Buy
- Analyst Count
- ARTV 5
- ITOS 3
- Target Price
- ARTV $21.25
- ITOS $25.33
- AVG Volume (30 Days)
- ARTV 45.7K
- ITOS 448.3K
- Earning Date
- ARTV 11-12-2024
- ITOS 11-12-2024
- Dividend Yield
- ARTV N/A
- ITOS N/A
- EPS Growth
- ARTV N/A
- ITOS N/A
- EPS
- ARTV N/A
- ITOS N/A
- Revenue
- ARTV $2,601,000.00
- ITOS $35,000,000.00
- Revenue This Year
- ARTV N/A
- ITOS $271.18
- Revenue Next Year
- ARTV N/A
- ITOS N/A
- P/E Ratio
- ARTV N/A
- ITOS N/A
- Revenue Growth
- ARTV N/A
- ITOS N/A
- 52 Week Low
- ARTV $9.68
- ITOS $7.44
- 52 Week High
- ARTV $17.31
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- ARTV N/A
- ITOS 34.10
- Support Level
- ARTV N/A
- ITOS $7.44
- Resistance Level
- ARTV N/A
- ITOS $7.96
- Average True Range (ATR)
- ARTV 0.00
- ITOS 0.34
- MACD
- ARTV 0.00
- ITOS -0.02
- Stochastic Oscillator
- ARTV 0.00
- ITOS 9.97
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.